Literature DB >> 34314079

Tazarotene-induced gene 1 interacts with Polo-like kinase 2 and inhibits cell proliferation in HCT116 colorectal cancer cells.

Chun-Hua Wang1,2, Tzung-Ju Lu2,3, Lu-Kai Wang4, Chang-Chieh Wu5, Mao-Liang Chen6, Chan-Yen Kuo6, Rong-Yaun Shyu7, Fu-Ming Tsai6.   

Abstract

Tazarotene-induced gene 1 (TIG1) is considered to be a tumor suppressor gene that is highly expressed in normal or well-differentiated colon tissues, while downregulation of TIG1 expression occurs in poorly differentiated colorectal cancer (CRC) tissues. However, it is still unclear how TIG1 regulates the tumorigenesis of CRC. Polo-like kinases (Plks) are believed to play an important role in regulating the cell cycle. The performance of PLK2 in CRC is negatively correlated with the differentiation status of CRC tissues. Here, we found that PLK2 can induce the growth of CRC cells and that TIG1 can prevent PLK2 from promoting the proliferation of CRC cells. We also found that the expression of PLK2 in CRC cells was associated with low levels of Fbxw7 protein and increased expression of cyclin E1. When TIG1 was coexpressed with PLK2, the changes in Fbxw7/cyclin E1 levels induced by PLK2 were reversed. In contrast, silencing TIG1 promoted the proliferation of CRC, and when PLK2 was also silenced, the proliferation of CRC cells induced by TIG1 silencing was significantly inhibited. The above research results suggest that TIG1 can regulate the tumorigenesis of CRC by regulating the activity of PLK2.
© 2021 International Federation for Cell Biology.

Entities:  

Keywords:  Fbxw7; Polo-like kinases; cell proliferation; cyclin E1; tazarotene-induced gene 1

Mesh:

Substances:

Year:  2021        PMID: 34314079     DOI: 10.1002/cbin.11681

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  1 in total

Review 1.  Polo-Like Kinase 2: From Principle to Practice.

Authors:  Chuanyong Zhang; Chuangye Ni; Hao Lu
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.